A detailed history of Black Rock Inc. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Black Rock Inc. holds 6,391,472 shares of AVXL stock, worth $62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,391,472
Previous 6,645,538 3.82%
Holding current value
$62 Million
Previous $33.8 Million 20.26%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$3.39 - $5.02 $861,283 - $1.28 Million
-254,066 Reduced 3.82%
6,391,472 $27 Million
Q1 2024

May 10, 2024

SELL
$4.55 - $6.75 $116,193 - $172,374
-25,537 Reduced 0.38%
6,645,538 $33.8 Million
Q4 2023

Feb 13, 2024

BUY
$5.04 - $9.95 $3.07 Million - $6.07 Million
609,884 Added 10.06%
6,671,075 $62.1 Million
Q3 2023

Nov 13, 2023

BUY
$6.55 - $9.37 $800,560 - $1.15 Million
122,223 Added 2.06%
6,061,191 $39.7 Million
Q2 2023

Aug 11, 2023

BUY
$7.66 - $9.5 $1.54 Million - $1.91 Million
201,318 Added 3.51%
5,938,968 $48.3 Million
Q1 2023

May 12, 2023

BUY
$8.32 - $11.75 $1.33 Million - $1.87 Million
159,491 Added 2.86%
5,737,650 $49.2 Million
Q4 2022

Feb 13, 2023

BUY
$7.65 - $14.43 $2.02 Million - $3.81 Million
263,982 Added 4.97%
5,578,159 $51.7 Million
Q3 2022

Nov 14, 2022

SELL
$8.9 - $12.86 $359,168 - $518,978
-40,356 Reduced 0.75%
5,314,177 $54.8 Million
Q2 2022

Aug 12, 2022

BUY
$7.31 - $12.84 $210,155 - $369,137
28,749 Added 0.54%
5,354,533 $53.6 Million
Q1 2022

May 12, 2022

BUY
$9.74 - $17.69 $614,769 - $1.12 Million
63,118 Added 1.2%
5,325,784 $65.6 Million
Q4 2021

Feb 10, 2022

BUY
$16.88 - $23.31 $14 Million - $19.3 Million
829,565 Added 18.71%
5,262,666 $91.3 Million
Q3 2021

Nov 09, 2021

BUY
$16.82 - $25.75 $2.03 Million - $3.11 Million
120,633 Added 2.8%
4,433,101 $79.6 Million
Q2 2021

Aug 11, 2021

BUY
$10.16 - $28.86 $43.8 Million - $124 Million
4,312,468 New
4,312,468 $98.6 Million

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $756M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.